Parathyroid hormone (PTH) has been shown in vitro to enhance erythrocyte osmotic fragility (EOF) and has been incriminated as a factor in the anaemia seen in patients with primary hyperparathyroidism and in patients with renal disease and secondary hyperparathyroidism. Enhanced EOF has also been shown in patients with chronic renal failure but did not correlate with PTH levels. We studied a group ofpatients with primary hyperparathyroidism with and without anaemia, and patients with secondary hyperparathyroidism and anaemia. We found that EOF studies in these patients did not differ from normal control groups and that there was no relation between PTH, EOF, and haematocrit in either study group. We conclude that PTH over a range of concentrations seen in vivo does not affect erythrocyte osmotic fragility or cause anaemia.
Summary:
Parathyroid hormone (PTH) has been shown in vitro to enhance erythrocyte osmotic fragility (EOF) and has been incriminated as a factor in the anaemia seen in patients with primary hyperparathyroidism and in patients with renal disease and secondary hyperparathyroidism. Enhanced EOF has also been shown in patients with chronic renal failure but did not correlate with PTH levels. We studied a group ofpatients with primary hyperparathyroidism with and without anaemia, and patients with secondary hyperparathyroidism and anaemia. We found that EOF studies in these patients did not differ from normal control groups and that there was no relation between PTH, EOF, and haematocrit in either study group. We conclude that PTH over a range of concentrations seen in vivo does not affect erythrocyte osmotic fragility or cause anaemia.
Introouction
Patients with primary hyperparathyroidism are occasionally found to have a normochromic, normocytic anaemia. 14 This anaemia has been the subject of interest because the same mechanisms producing anaemia in patients with primary hyperparathyroidism may be operative in patients with chronic renal failure who also have elevated parathyroid hormone levels. Parathyroid hormone (PTH) has been reported to cause both bone marrow suppression5 and increased erythrocyte osmotic fragility (EOF) in vitro.6'7 We therefore studied patients with mild primary hyperparathyroidism, primary hyperparathyroidism requiring surgery, and secondary hyperparathyroidism to determine if in vivo effects of PTH on EOF could be demonstrated.
Methods
Two sets of patients were selected prospectively for investigation of EOF. One was a group of patients (n = 14) with primary hyperparathyroidism undergoing a longitudinal study of the effects of PTH on renal function and the other was a group of haemodialysis patients (n = 20) who were stable and had been maintained on haemodialysis for at least 4 months (46 ± 0.8 months). Control data were obtained from 15 healthy volunteers aged 28-35 who were either staff physicians or physicians in training who took no chronic medications. The research protocol was approved by the Brooke Army Medical Center Clinical Investigation and Human Use Committees in accordance with the Helsinki Declaration of 1975.
No patients were taking medications known to suppress PTH.8 All blood specimens were obtained between 07.00-08.30 hours in the fasting condition. All specimens were drawn pre-dialysis in the dialysis patients. Multi-channel blood chemistry analysis was done with the Technicon SMAC-2 Auto-analyser and complete blood count and red blood cell (RBC) indices by Coulter Counter. EOF was determined by using the Becton-Dickinson UnopetteR system (Becton-Dickinson, Rutherford, NJ, USA), which is based on the method of Dacie and Vaughan,9 with the phosphate buffer modification described by Parpart el al.'0 All EOF testing was completed within 20 minutes of RBC dilution. EOF studies ofthe control group and each experimental group were performed simultaneously. PTH was measured using antisera against the amino-and carboxy-terminal portions of the PTH molecule in the patients with primary hyperparathyroidism. PTH in the dialysis patients was measured using antisera against the carboxy-terminal portion of PTH, the mid-molecule portion, and the intact hormone. All PTH testing was done by the Nichols Institute, San Juan Capistrano, California, USA. These two assays are comparable in specificity and they differ with respect to their normal ranges (Nichols Institute, data on file). Median osmotic fragility was calculated as that percent NaCl solution at which 50% haemolysis had occurred.
All patients with primary hyperparathyroidism had hypercalcaemia and an inappropriately elevated PTH level, biochemical parameters consistent with primary hyperparathyroidism,4""',2 and had been followed by one of the authors (CJF) for over 5 years. All but one of the haemodialysis patients had significant secondary hyperparathyroidism.'3 In addition, the dialysis patients had normal hepatic transaminases, ferritin and bilirubin levels, reticulocyte (< 1.6%), and RBC indices.
Even though the PTH assays are comparable, the units differ. Accordingly, the PTH values are presented with the units and ranges appropriate for the assays. Data are expressed as the mean ± s.d. The median osmotic fragility, PTH, and haematocrits were compared using the Pearson Product-Moment Coefficient, and the Multiple Correlation Coefficient. The median osmotic fragility of control and experimental groups was also compared using the Wilcoxon rank sum test. Statistical significance was accepted as P < 0.05.
Results
EOF studies and median osmotic fragility values were not different between either the primary hyperparathyroid patients and the normal control group or between the dialysis patients and the normal control group (Table I ). Only two of the patients with primary hyperparathyroidism were anaemic (haematocrit < 38%), but all of the dialysis patients were anaemic. There was no difference in EOF or median osmotic fragility between the anaemic and non-anaemic patients. There was no correlation between PTH, haematocrit, or median osmotic fragility in any group (Table I) EOF studies were normal in patients with primary hyperparathyroidism with and without anaemia, including those patients who subsequently required surgery. Dialysis patients with anaemia and marked secondary hyperparathyroidism also had normal EOF studies. There was no relationship in either group between the level of anaemia and the concentration of PTH. We conclude that PTH found in various in vivo states had no effect on either anaemia or EOF.
